Christie Ballantyne, MD

Christie Ballantyne is an internationally renowned expert on lipids, atherosclerosis, and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the AHA and to receive continuous funding from the NIH since in 1988 in basic research of leukocyte–endothelial interactions, translational research in biomarkers, and clinical trials.

Show full bio

Dr. Ballantyne’s  many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012 he received the American College of Cardiology Distinguished Scientist Award (Basic Domain). In 2014 and 2015, Thomson Reuters recognized Christie as one of “The World’s Most Influential Scientific Minds.” Clarivate Analytics, Web of Science, named Dr. Ballantyne as a “Highly Cited Researcher” 2017-2022 in the top 1% of researchers most cited. In 2019, Dr. Ballantyne was awarded the Baylor College of Medicine Michael E. DeBakey, M.D., Excellence in Research Award. His research in biomarkers has led to the FDA approval of 2 biomarkers for cardiovascular risk prediction, and he has played a prominent role in the development and FDA approval of new therapies for treatment of lipids.

With over 1,000 publications in the area of atherosclerosis, lipids and inflammation, Christie also serves on the Editorial Board for Circulation and JACC. Christie is the Chief of Cardiology and Cardiovascular Research at Baylor College of Medicine. He is currently the Director for Cardiometabolic Disease Prevention at Baylor College of Medicine.

He received his MD from Baylor College of Medicine with internal medicine residency at The University of Texas Southwestern Medical School and cardiology fellowship at Baylor College of Medicine and an AHA fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.

See Publications

Texas Heart Institute Positions

Education

  • Undergraduate:

    University of Texas at Austin

  • Medical School:

    Baylor College of Medicine

  • Residency:

    University of Texas Southwestern Affiliate Hospitals

  • Fellowships:

    Baylor College of Medicine Affiliate Hospitals

Academic & Clinical Affiliations

Honors, Awards and Memberships

Publications

4862227 SIH54GGA 1 alternatives-to-animal-experimentation 10 date desc Ballantyne 1817 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%228SZXB9MC%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ijaz%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BIjaz%2C%20S.%20H.%2C%20Minhas%2C%20A.%20M.%20K.%2C%20Jain%2C%20V.%20et%20al.%20%282023%29.%20Characteristics%20and%20outcomes%20in%20acute%20myocardial%20infarction%20hospitalizations%20among%20the%20older%20population%20%28age%20%26%23x2265%3B80%20years%29%20in%20the%20United%20States%2C%202004-2018.%20%26lt%3Bi%26gt%3BArch%20Gerontol%20Geriatr%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B111%26lt%3B%5C%2Fi%26gt%3B%2C%20104930.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.archger.2023.104930%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.archger.2023.104930%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Characteristics%20and%20outcomes%20in%20acute%20myocardial%20infarction%20hospitalizations%20among%20the%20older%20population%20%28age%20%5Cu226580%20years%29%20in%20the%20United%20States%2C%202004-2018%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sardar%20Hassan%22%2C%22lastName%22%3A%22Ijaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdul%20Mannan%20Khan%22%2C%22lastName%22%3A%22Minhas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vardhmaan%22%2C%22lastName%22%3A%22Jain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmoud%20Al%22%2C%22lastName%22%3A%22Rifai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Garima%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anurag%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sourbha%20S.%22%2C%22lastName%22%3A%22Dani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marat%22%2C%22lastName%22%3A%22Fudim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sadeer%20G.%22%2C%22lastName%22%3A%22Al-Kindi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Sperling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20D.%22%2C%22lastName%22%3A%22Shapiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahboob%22%2C%22lastName%22%3A%22Alam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20S.%22%2C%22lastName%22%3A%22Virani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sachin%20S.%22%2C%22lastName%22%3A%22Goel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khurram%22%2C%22lastName%22%3A%22Nasir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Safi%20U.%22%2C%22lastName%22%3A%22Khan%22%7D%5D%2C%22abstractNote%22%3A%22IMPORTANCE%3A%20Acute%20myocardial%20infarction%20%28AMI%29%20is%20a%20major%20health%20concern%20among%20older%20adults%20%28%5Cu226580%20years%29.%20We%20analyzed%20a%20US%20national%20database%20to%20evaluate%20the%20clinical%20outcomes%2C%20resource%20utilization%2C%20and%20economic%20burden%20of%20AMI%20hospitalizations%20in%20older%20patients.%5CnMETHODS%20AND%20RESULTS%3A%20We%20analyzed%20the%20National%20Inpatient%20Sample%20data%20between%20January%202004%20and%20December%202018.%20We%20examined%20the%20trends%20of%20clinical%20characteristics%2C%20inpatient%20mortality%2C%20and%20healthcare%20cost%20utilization%20in%20older%20US%20adults%20for%20AMI%20hospitalizations.%20We%20identified%202%2C174%2C587%20weighted%20AMI%20hospitalizations.%20There%20was%20a%20decrease%20in%20AMI%20hospitalizations%20per%20100%2C000%20older%20US%20adults%20from%201%2C679%20in%202004%20to%201036%20in%202018%2C%20with%20a%20more%20profound%20decrease%20in%20ST-elevation%20myocardial%20infarction%20%28STEMI%29.%20We%20noted%20an%20overall%20increase%20in%20comorbidities%20%28hypertension%2C%20heart%20failure%2C%20dyslipidemia%2C%20atrial%20fibrillation%2C%20diabetes%2C%20peripheral%20vascular%20disease%29.%20Overall%2C%20inpatient%20mortality%20was%2010.6%25%3B%20adjusted%20inpatient%20mortality%20decreased%20from%2014%25%20in%202004%20to%208%25%20in%202018%20%28p%20trend%20%26lt%3B0.001%29-%20consistent%20across%20sexes%20and%20races.%20There%20was%20increased%20percutaneous%20intervention%20%28PCI%29%20utilization%20%5B19.3%25%20%282004-2008%29%20to%2024.0%25%20%282014-2018%29%5D%20with%20a%20concomitant%20increase%20in%20bleeding%20and%20acute%20kidney%20injury%20%28AKI%29.%20Black%20adults%20and%20women%20underwent%20revascularization%20less%20frequently%20than%20White%20adults%20and%20men.%20White%20patients%20had%20higher%20inpatient%20mortality%20compared%20to%20black%20patients.%20There%20was%20a%20decrease%20in%20adjusted%20mean%20length%20of%20stay%20%28LOS%29%20from%206.2%20days%20in%202004%20to%203.9%20days%20in%202018%20%28p%20trend%20%26lt%3B0.001%29.%20There%20was%20an%20increase%20in%20discharge%20disposition%20to%20home%20with%20a%20concomitant%20decrease%20in%20utilization%20of%20rehabilitation%20facilities%20at%20discharge.%5CnCONCLUSION%3A%20Our%20study%20showed%20that%20the%20inpatient%20mortality%20and%20LOS%20has%20decreased%20for%20AMI%20hospitalizations%20in%20the%20older%20patient%20population%20in%20the%20US.%20While%20utilization%20of%20revascularization%20strategies%20has%20increased%2C%20sex%20and%20racial%20disparities%20exist%20in%20the%20utilization%20of%20PCI.%22%2C%22date%22%3A%222023-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.archger.2023.104930%22%2C%22ISSN%22%3A%221872-6976%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22ZL4RPFGU%22%2C%22SIH54GGA%22%2C%22FCV4W3RS%22%2C%22NTAHPDUG%22%2C%224U5B8N6T%22%5D%2C%22dateModified%22%3A%222023-06-08T13%3A54%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22JDEPPUY2%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ballantyne%20and%20Jia%22%2C%22parsedDate%22%3A%222023-07-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BBallantyne%26lt%3B%5C%2Fstrong%26gt%3B%2C%20C.%20M.%20and%20Jia%2C%20X.%20%282023%29.%20Omega-3%20fatty%20acids%20and%20risk%20for%20atrial%26%23xA0%3Bfibrillation%3A%20big%20fish%20or%20small%20fry%3F%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B82%26lt%3B%5C%2Fi%26gt%3B%2C%20350%26%23x2013%3B352.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2023.05.026%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2023.05.026%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Omega-3%20fatty%20acids%20and%20risk%20for%20atrial%5Cu00a0fibrillation%3A%20big%20fish%20or%20small%20fry%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoming%22%2C%22lastName%22%3A%22Jia%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-07-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2023.05.026%22%2C%22ISSN%22%3A%221558-3597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%22LIMU9MDX%22%5D%2C%22dateModified%22%3A%222023-07-27T16%3A57%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22NTSXIKVL%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Walker%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWalker%2C%20K.%20A.%2C%20Chen%2C%20J.%2C%20Shi%2C%20L.%20et%20al.%20%282023%29.%20Proteomics%20analysis%20of%20plasma%20from%20middle-aged%20adults%20identifies%20protein%20markers%20of%20dementia%20risk%20in%20later%20life.%20%26lt%3Bi%26gt%3BSci%20Transl%20Med%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B15%26lt%3B%5C%2Fi%26gt%3B%2C%20eadf5681.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.adf5681%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.adf5681%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Proteomics%20analysis%20of%20plasma%20from%20middle-aged%20adults%20identifies%20protein%20markers%20of%20dementia%20risk%20in%20later%20life%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keenan%20A.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jingsha%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liu%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yunju%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Fornage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Schlosser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aditya%22%2C%22lastName%22%3A%22Surapaneni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgan%20E.%22%2C%22lastName%22%3A%22Grams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20R.%22%2C%22lastName%22%3A%22Duggan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhongsheng%22%2C%22lastName%22%3A%22Peng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%20T.%22%2C%22lastName%22%3A%22Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrienne%22%2C%22lastName%22%3A%22Tin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ron%20C.%22%2C%22lastName%22%3A%22Hoogeveen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20J.%22%2C%22lastName%22%3A%22Sullivan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Ganz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joni%20V.%22%2C%22lastName%22%3A%22Lindbohm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mika%22%2C%22lastName%22%3A%22Kivimaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejo%20J.%22%2C%22lastName%22%3A%22Nevado-Holgado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noel%22%2C%22lastName%22%3A%22Buckley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%20F.%22%2C%22lastName%22%3A%22Gottesman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20H.%22%2C%22lastName%22%3A%22Mosley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Boerwinkle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josef%22%2C%22lastName%22%3A%22Coresh%22%7D%5D%2C%22abstractNote%22%3A%22A%20diverse%20set%20of%20biological%20processes%20have%20been%20implicated%20in%20the%20pathophysiology%20of%20Alzheimer%26%23039%3Bs%20disease%20%28AD%29%20and%20related%20dementias.%20However%2C%20there%20is%20limited%20understanding%20of%20the%20peripheral%20biological%20mechanisms%20relevant%20in%20the%20earliest%20phases%20of%20the%20disease.%20Here%2C%20we%20used%20a%20large-scale%20proteomics%20platform%20to%20examine%20the%20association%20of%204877%20plasma%20proteins%20with%2025-year%20dementia%20risk%20in%2010%2C981%20middle-aged%20adults.%20We%20found%2032%20dementia-associated%20plasma%20proteins%20that%20were%20involved%20in%20proteostasis%2C%20immunity%2C%20synaptic%20function%2C%20and%20extracellular%20matrix%20organization.%20We%20then%20replicated%20the%20association%20between%2015%20of%20these%20proteins%20and%20clinically%20relevant%20neurocognitive%20outcomes%20in%20two%20independent%20cohorts.%20We%20demonstrated%20that%2012%20of%20these%2032%20dementia-associated%20proteins%20were%20associated%20with%20cerebrospinal%20fluid%20%28CSF%29%20biomarkers%20of%20AD%2C%20neurodegeneration%2C%20or%20neuroinflammation.%20We%20found%20that%20eight%20of%20these%20candidate%20protein%20markers%20were%20abnormally%20expressed%20in%20human%20postmortem%20brain%20tissue%20from%20patients%20with%20AD%2C%20although%20some%20of%20the%20proteins%20that%20were%20most%20strongly%20associated%20with%20dementia%20risk%2C%20such%20as%20GDF15%2C%20were%20not%20detected%20in%20these%20brain%20tissue%20samples.%20Using%20network%20analyses%2C%20we%20found%20a%20protein%20signature%20for%20dementia%20risk%20that%20was%20characterized%20by%20dysregulation%20of%20specific%20immune%20and%20proteostasis%5C%2Fautophagy%20pathways%20in%20adults%20in%20midlife%20~20%20years%20before%20dementia%20onset%2C%20as%20well%20as%20abnormal%20coagulation%20and%20complement%20signaling%20~10%20years%20before%20dementia%20onset.%20Bidirectional%20two-sample%20Mendelian%20randomization%20genetically%20validated%20nine%20of%20our%20candidate%20proteins%20as%20markers%20of%20AD%20in%20midlife%20and%20inferred%20causality%20of%20SERPINA3%20in%20AD%20pathogenesis.%20Last%2C%20we%20prioritized%20a%20set%20of%20candidate%20markers%20for%20AD%20and%20dementia%20risk%20prediction%20in%20midlife.%22%2C%22date%22%3A%222023-07-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1126%5C%2Fscitranslmed.adf5681%22%2C%22ISSN%22%3A%221946-6242%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%22LIMU9MDX%22%5D%2C%22dateModified%22%3A%222023-07-27T16%3A51%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22EWD3F2LP%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jia%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJia%2C%20X.%2C%20Buckley%2C%20L.%2C%20Sun%2C%20C.%20et%20al.%20%282023%29.%20Association%20of%20interleukin-6%20and%20interleukin-18%20with%20cardiovascular%20disease%20in%20older%20adults%3A%20Atherosclerosis%20risk%20in%20communities%20study.%20%26lt%3Bi%26gt%3BEur%20J%20Prev%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%2C%20zwad197.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Feurjpc%5C%2Fzwad197%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Feurjpc%5C%2Fzwad197%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20interleukin-6%20and%20interleukin-18%20with%20cardiovascular%20disease%20in%20older%20adults%3A%20Atherosclerosis%20risk%20in%20communities%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoming%22%2C%22lastName%22%3A%22Jia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leo%22%2C%22lastName%22%3A%22Buckley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmoud%22%2C%22lastName%22%3A%22Al%20Rifai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bing%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Nambi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20S.%22%2C%22lastName%22%3A%22Virani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Selvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kunihiro%22%2C%22lastName%22%3A%22Matsushita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ron%20C.%22%2C%22lastName%22%3A%22Hoogeveen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josef%22%2C%22lastName%22%3A%22Coresh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amil%20M.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20Interleukin-6%20%28IL-6%29%20and%20interleukin-18%20%28IL-18%29%2C%20important%20cytokines%20implicated%20in%20atherosclerosis%20and%20inflammaging%2C%20were%20assessed%20for%20associations%20with%20global%20cardiovascular%20disease%20%28CVD%29%2C%20atrial%20fibrillation%20%28AF%29%2C%20and%20death%20in%20older%20adults.%5CnMETHODS%3A%20Participants%20from%20Atherosclerosis%20Risk%20in%20Communities%20study%20visit%205%20%28mean%20age%2075.4%5Cu2009%5Cu00b1%5Cu20095.1%20years%29%20with%20IL-6%20and%20IL-18%20measurements%20were%20included%20%28N%5Cu2009%3D%5Cu20095672%29.%20Cox%20regression%20models%20were%20used%20to%20assess%20associations%20of%20IL-6%20and%20IL-18%20with%20coronary%20heart%20disease%20%28CHD%29%2C%20ischemic%20stroke%2C%20heart%20failure%20hospitalization%20%28HF%29%2C%20global%20CVD%20%28composite%20of%20CHD%2C%20stroke%2C%20and%20HF%29%2C%20AF%2C%20and%20all-cause%20death.%5CnRESULTS%3A%20Over%20a%20median%20follow-up%20of%207.2%20years%2C%20there%20were%201235%20global%20CVD%20events%2C%20530%20AF%20events%2C%20and%201173%20deaths.%20Higher%20IL-6%20%28hazard%20ratio%20%5BHR%5D%201.57%2C%2095%25%20confidence%20interval%20%5BCI%5D%201.44-1.72%20per%20log%20unit%20increase%29%20and%20IL-18%20%28HR%201.13%2C%2095%25%20CI%201.01-1.26%29%20were%20significantly%20associated%20with%20global%20CVD%20after%20adjustment%20for%20cardiovascular%20risk%20factors.%20Association%20between%20IL-6%20and%20global%20CVD%20remained%20significant%20after%20further%20adjustment%20for%20high-sensitivity%20C-reactive%20protein%20%28hs-CRP%29%2C%20N-terminal%20B%20type%20natriuretic%20peptide%20%28NT-proBNP%29%2C%20and%20high-sensitivity%20troponin%20T%20%28hs-TnT%29%2C%20but%20was%20no%20longer%20significant%20for%20IL-18%20after%20further%20adjustments.%20IL-6%20was%20also%20associated%20with%20increased%20risk%20for%20CHD%2C%20HF%2C%20and%20AF%20after%20adjustment%20for%20covariates.%20Both%20IL-6%20and%20IL-18%20were%20associated%20with%20increased%20risk%20for%20all-cause%20death%20independent%20of%20cardiovascular%20risk%20factors%20and%20other%20biomarkers.%5CnCONCLUSION%3A%20Among%20older%20adults%2C%20both%20IL-6%20and%20IL-18%20were%20associated%20with%20global%20CVD%20and%20death.%20The%20association%20between%20IL-6%20with%20CVD%20appears%20to%20be%20more%20robust%20and%20was%20independent%20of%20hs-CRP%2C%20NT-proBNP%2C%20and%20hs-TnT.%22%2C%22date%22%3A%222023-06-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Feurjpc%5C%2Fzwad197%22%2C%22ISSN%22%3A%222047-4881%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%22FCV4W3RS%22%2C%22Q46ISS7S%22%5D%2C%22dateModified%22%3A%222023-07-21T19%3A08%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22L3P73KB7%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kiernan%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKiernan%2C%20E.%2C%20Surapaneni%2C%20A.%2C%20Zhou%2C%20L.%20et%20al.%20%282023%29.%20Alterations%20in%20the%20circulating%20proteome%20associated%20with%20albuminuria.%20%26lt%3Bi%26gt%3BJ%20Am%20Soc%20Nephrol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B34%26lt%3B%5C%2Fi%26gt%3B%2C%201078%26%23x2013%3B1089.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1681%5C%2FASN.0000000000000108%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1681%5C%2FASN.0000000000000108%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Alterations%20in%20the%20circulating%20proteome%20associated%20with%20albuminuria%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Kiernan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aditya%22%2C%22lastName%22%3A%22Surapaneni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Schlosser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keenan%20A.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%20P.%22%2C%22lastName%22%3A%22Rhee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajat%22%2C%22lastName%22%3A%22Deo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruth%20F.%22%2C%22lastName%22%3A%22Dubin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Ganz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josef%22%2C%22lastName%22%3A%22Coresh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgan%20E.%22%2C%22lastName%22%3A%22Grams%22%7D%5D%2C%22abstractNote%22%3A%22SIGNIFICANCE%20STATEMENT%3A%20We%20describe%20circulating%20proteins%20associated%20with%20albuminuria%20in%20a%20population%20of%20African%20American%20Study%20of%20Kidney%20Disease%20and%20Hypertension%20with%20CKD%20%28AASK%29%20using%20the%20largest%20proteomic%20platform%20to%20date%3A%20nearly%207000%20circulating%20proteins%2C%20representing%20approximately%202000%20new%20targets.%20Findings%20were%20replicated%20in%20a%20subset%20of%20a%20general%20population%20cohort%20with%20kidney%20disease%20%28ARIC%29%20and%20a%20population%20with%20CKD%20Chronic%20Renal%20Insufficiency%20Cohort%20%28CRIC%29.%20In%20cross-sectional%20analysis%2C%20104%20proteins%20were%20significantly%20associated%20with%20albuminuria%20in%20the%20Black%20group%2C%20of%20which%2067%20of%2077%20available%20proteins%20were%20replicated%20in%20ARIC%20and%2068%20of%2071%20available%20proteins%20in%20CRIC.%20LMAN2%2C%20TNFSFR1B%2C%20and%20members%20of%20the%20ephrin%20superfamily%20had%20the%20strongest%20associations.%20Pathway%20analysis%20also%20demonstrated%20enrichment%20of%20ephrin%20family%20proteins.%5CnBACKGROUND%3A%20Proteomic%20techniques%20have%20facilitated%20understanding%20of%20pathways%20that%20mediate%20decline%20in%20GFR.%20Albuminuria%20is%20a%20key%20component%20of%20CKD%20diagnosis%2C%20staging%2C%20and%20prognosis%20but%20has%20been%20less%20studied%20than%20GFR.%20We%20sought%20to%20investigate%20circulating%20proteins%20associated%20with%20higher%20albuminuria.%5CnMETHODS%3A%20We%20evaluated%20the%20cross-sectional%20associations%20of%20the%20blood%20proteome%20with%20albuminuria%20and%20longitudinally%20with%20doubling%20of%20albuminuria%20in%20the%20African%20American%20Study%20of%20Kidney%20Disease%20and%20Hypertension%20%28AASK%3B%2038%25%20female%3B%20mean%20GFR%2046%3B%20median%20urine%20protein-to-creatinine%20ratio%2081%20mg%5C%2Fg%3B%20n%20%3D703%29%20and%20replicated%20in%20two%20external%20cohorts%3A%20a%20subset%20of%20the%20Atherosclerosis%20Risk%20in%20Communities%20%28ARIC%29%20study%20with%20CKD%20and%20the%20Chronic%20Renal%20Insufficiency%20Cohort%20%28CRIC%29.%5CnRESULTS%3A%20In%20cross-sectional%20analysis%2C%20104%20proteins%20were%20significantly%20associated%20with%20albuminuria%20in%20AASK%2C%20of%20which%2067%20of%2077%20available%20proteins%20were%20replicated%20in%20ARIC%20and%2068%20of%2071%20available%20proteins%20in%20CRIC.%20Proteins%20with%20the%20strongest%20associations%20included%20LMAN2%2C%20TNFSFR1B%2C%20and%20members%20of%20the%20ephrin%20superfamily.%20Pathway%20analysis%20also%20demonstrated%20enrichment%20of%20ephrin%20family%20proteins.%20Five%20proteins%20were%20significantly%20associated%20with%20worsening%20albuminuria%20in%20AASK%2C%20including%20LMAN2%20and%20EFNA4%2C%20which%20were%20replicated%20in%20ARIC%20and%20CRIC.%5CnCONCLUSIONS%3A%20Among%20individuals%20with%20CKD%2C%20large-scale%20proteomic%20analysis%20identified%20known%20and%20novel%20proteins%20associated%20with%20albuminuria%20and%20suggested%20a%20role%20for%20ephrin%20signaling%20in%20albuminuria%20progression.%22%2C%22date%22%3A%222023-06-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1681%5C%2FASN.0000000000000108%22%2C%22ISSN%22%3A%221533-3450%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%22BNSCCUCI%22%5D%2C%22dateModified%22%3A%222023-06-08T14%3A01%3A28Z%22%7D%7D%2C%7B%22key%22%3A%225HTFHF78%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ballantyne%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-31%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BBallantyne%26lt%3B%5C%2Fstrong%26gt%3B%2C%20C.%20M.%2C%20Ditmarsch%2C%20M.%2C%20Kastelein%2C%20J.%20J.%20et%20al.%20%282023%29.%20Obicetrapib%20plus%20ezetimibe%20as%20an%20adjunct%20to%20high-intensity%20statin%20therapy%3A%20A%20randomized%20phase%202%20trial.%20%26lt%3Bi%26gt%3BJ%20Clin%20Lipidol%26lt%3B%5C%2Fi%26gt%3B%2C%20S1933-2874%2823%2900186%26%23x2013%3B1.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacl.2023.05.098%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacl.2023.05.098%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Obicetrapib%20plus%20ezetimibe%20as%20an%20adjunct%20to%20high-intensity%20statin%20therapy%3A%20A%20randomized%20phase%202%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Ditmarsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20Jp%22%2C%22lastName%22%3A%22Kastelein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%20J.%22%2C%22lastName%22%3A%22Nelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Douglas%22%2C%22lastName%22%3A%22Kling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Hsieh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danielle%20L.%22%2C%22lastName%22%3A%22Curcio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20C.%22%2C%22lastName%22%3A%22Maki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20H.%22%2C%22lastName%22%3A%22Davidson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20J.%22%2C%22lastName%22%3A%22Nicholls%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Obicetrapib%2C%20a%20selective%20cholesteryl%20ester%20transfer%20protein%20%28CETP%29%20inhibitor%2C%20reduces%20low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%2C%20non-high-density%20lipoprotein%20cholesterol%20%28non-HDL-C%29%2C%20lipoprotein%20particles%2C%20and%20apolipoproteins%2C%20when%20added%20to%20high-intensity%20statin%20in%20patients%20with%20dyslipidemia.%5CnOBJECTIVE%3A%20To%20evaluate%20the%20safety%20and%20lipid-altering%20efficacy%20of%20obicetrapib%20plus%20ezetimibe%20combination%20therapy%20as%20an%20adjunct%20to%20high-intensity%20statin%20therapy.%5CnMETHODS%3A%20This%20double-blind%2C%20randomized%2C%20phase%202%20trial%20administered%2010%5Cu00a0mg%20obicetrapib%20plus%2010%5Cu00a0mg%20ezetimibe%20%28n%5Cu00a0%3D%5Cu00a040%29%2C%2010%5Cu00a0mg%20obicetrapib%20%28n%5Cu00a0%3D%5Cu00a039%29%2C%20or%20placebo%20%28n%5Cu00a0%3D%5Cu00a040%29%20for%2012%20weeks%20to%20patients%20with%20LDL-C%20%26gt%3B70%5Cu00a0mg%5C%2FdL%20and%20triglycerides%20%28TG%29%20%26lt%3B400%5Cu00a0mg%5C%2FdL%2C%20on%20stable%20high-intensity%20statin.%20Endpoints%20included%20concentrations%20of%20lipids%2C%20apolipoproteins%2C%20lipoprotein%20particles%2C%20and%20proprotein%20convertase%20subtilisin%20kexin%20type%209%20%28PCSK9%29%2C%20safety%2C%20and%20tolerability.%5CnRESULTS%3A%20Ninety-seven%20patients%20were%20included%20in%20the%20primary%20analysis%20%28mean%20age%2062.6%20years%2C%2063.9%25%20male%2C%2084.5%25%20white%2C%20average%20body%20mass%20index%20of%2030.9%5Cu00a0kg%5C%2Fm2%29.%20LDL-C%20decreased%20from%20baseline%20to%20week%2012%20by%2063.4%25%2C%2043.5%25%2C%20and%206.35%25%20in%20combination%2C%20monotherapy%2C%20and%20placebo%20groups%2C%20respectively%20%28p%26lt%3B0.0001%5Cu00a0vs.%20placebo%29.%20LDL-C%20levels%20of%20%26lt%3B100%2C%20%26lt%3B70%2C%20and%20%26lt%3B55%5Cu00a0mg%5C%2FdL%20were%20achieved%20by%20100%25%2C%2093.5%25%2C%20and%2087.1%25%2C%20respectively%2C%20of%20patients%20taking%20the%20combination.%20Both%20active%20treatments%20also%20significantly%20reduced%20concentrations%20of%20non-HDL-C%2C%20apolipoprotein%20B%2C%20and%20total%20and%20small%20LDL%20particles.%20Obicetrapib%20was%20well%20tolerated%20and%20no%20safety%20issues%20were%20identified.%5CnCONCLUSION%3A%20The%20combination%20of%20obicetrapib%20plus%20ezetimibe%20significantly%20lowered%20atherogenic%20lipid%20and%20lipoprotein%20parameters%2C%20and%20was%20safe%20and%20well%20tolerated%20when%20administered%20on%20top%20of%20high-intensity%20statin%20to%20patients%20with%20elevated%20LDL-C.%22%2C%22date%22%3A%222023-05-31%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacl.2023.05.098%22%2C%22ISSN%22%3A%221933-2874%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%22Q46ISS7S%22%5D%2C%22dateModified%22%3A%222023-07-21T18%3A37%3A37Z%22%7D%7D%2C%7B%22key%22%3A%224W38M44E%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhang%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BZhang%2C%20Y.%2C%20Dron%2C%20J.%20S.%2C%20Bellows%2C%20B.%20K.%20et%20al.%20%282023%29.%20Association%20of%20severe%20hypercholesterolemia%20and%20familial%20hypercholesterolemia%20genotype%20with%20risk%20of%20coronary%20heart%20disease.%20%26lt%3Bi%26gt%3BCirculation%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B147%26lt%3B%5C%2Fi%26gt%3B%2C%201556%26%23x2013%3B1559.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCULATIONAHA.123.064168%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCULATIONAHA.123.064168%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20severe%20hypercholesterolemia%20and%20familial%20hypercholesterolemia%20genotype%20with%20risk%20of%20coronary%20heart%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yiyi%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%20S.%22%2C%22lastName%22%3A%22Dron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brandon%20K.%22%2C%22lastName%22%3A%22Bellows%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amit%20V.%22%2C%22lastName%22%3A%22Khera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junxiu%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pallavi%20P.%22%2C%22lastName%22%3A%22Balte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20C.%22%2C%22lastName%22%3A%22Oelsner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sami%20Samir%22%2C%22lastName%22%3A%22Amr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20S.%22%2C%22lastName%22%3A%22Lebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Nagy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gina%20M.%22%2C%22lastName%22%3A%22Peloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pradeep%22%2C%22lastName%22%3A%22Natarajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%20I.%22%2C%22lastName%22%3A%22Rotter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristen%22%2C%22lastName%22%3A%22Willer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Boerwinkle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20L.%22%2C%22lastName%22%3A%22Lutsey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Fornage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donald%20M.%22%2C%22lastName%22%3A%22Lloyd-Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lifang%22%2C%22lastName%22%3A%22Hou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruce%20M.%22%2C%22lastName%22%3A%22Psaty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joshua%20C.%22%2C%22lastName%22%3A%22Bis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20S.%22%2C%22lastName%22%3A%22Floyd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramachandran%20S.%22%2C%22lastName%22%3A%22Vasan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%20L.%22%2C%22lastName%22%3A%22Heard-Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22April%20P.%22%2C%22lastName%22%3A%22Carson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20E.%22%2C%22lastName%22%3A%22Hall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20S.%22%2C%22lastName%22%3A%22Rich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiuqing%22%2C%22lastName%22%3A%22Guo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhruv%20S.%22%2C%22lastName%22%3A%22Kazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20D.%22%2C%22lastName%22%3A%22de%20Ferranti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20E.%22%2C%22lastName%22%3A%22Moran%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-05-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.123.064168%22%2C%22ISSN%22%3A%221524-4539%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T14%3A51%3A45Z%22%7D%7D%2C%7B%22key%22%3A%229X227XLK%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hussain%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHussain%2C%20A.%2C%20Ramsey%2C%20D.%2C%20Lee%2C%20M.%20et%20al.%20%282023%29.%20Utilization%20rates%20of%20SGLT2%20inhibitors%20among%20patients%20with%20type%202%20diabetes%2C%20heart%20failure%2C%20and%20atherosclerotic%20cardiovascular%20disease%3A%20Insights%20from%20the%20Department%20of%20Veterans%20Affairs.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%2C%20S2213-1779%2823%2900185%26%23x2013%3B3.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.024%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.024%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Utilization%20rates%20of%20SGLT2%20inhibitors%20among%20patients%20with%20type%202%20diabetes%2C%20heart%20failure%2C%20and%20atherosclerotic%20cardiovascular%20disease%3A%20Insights%20from%20the%20Department%20of%20Veterans%20Affairs%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aliza%22%2C%22lastName%22%3A%22Hussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Ramsey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhruv%22%2C%22lastName%22%3A%22Mahtta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammad%20Shahzeb%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Nambi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20A.%22%2C%22lastName%22%3A%22Petersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrienne%20D.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Waleed%20T.%22%2C%22lastName%22%3A%22Kayani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javed%22%2C%22lastName%22%3A%22Butler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leandro%22%2C%22lastName%22%3A%22Slipczuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Biykem%22%2C%22lastName%22%3A%22Bozkurt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sankar%20D.%22%2C%22lastName%22%3A%22Navaneethan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20S.%22%2C%22lastName%22%3A%22Virani%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Multiple%20clinical%20trials%20have%20demonstrated%20significant%20cardiovascular%20benefit%20with%20use%20of%20sodium-glucose%20cotransporter-2%20%28SGLT2%29%20inhibitors%20in%20patients%20with%20type%202%20diabetes%20%28T2DM%29%20and%20heart%20failure%20%28HF%29%20irrespective%20of%20ejection%20fraction.%20There%20are%20limited%20data%20evaluating%20real-world%20prescription%20and%20practice%20patterns%20of%20SGLT2%20inhibitors.%5CnOBJECTIVES%3A%20The%20authors%20sought%20to%20assess%20utilization%20rates%20and%20facility-level%20variation%20in%20the%20use%20among%20patients%20with%20established%20atherosclerotic%20cardiovascular%20disease%20%28ASCVD%29%2C%20HF%2C%20and%20T2DM%20using%20data%20from%20the%20nationwide%20Veterans%20Affairs%20health%20care%20system.%5CnMETHODS%3A%20The%20authors%20included%20patients%20with%20established%20ASCVD%2C%20HF%2C%20and%20T2DM%20seen%20by%20a%20primary%20care%20provider%20between%20January%201%2C%202020%2C%20and%20December%2031%2C%202020.%20They%20assessed%20the%20use%20of%20SGLT2%20inhibitors%20and%20the%20facility-level%20variation%20in%20their%20use.%20Facility-level%20variation%20was%20computed%20using%20median%20rate%20ratios%2C%20a%20measure%20of%20likelihood%20that%202%5Cu00a0random%20facilities%20differ%20in%20use%20of%20SGLT2%20inhibitors.%5CnRESULTS%3A%20Among%20105%2C799%20patients%20with%20ASCVD%2C%20HF%2C%20and%20T2DM%20across%20130%20Veterans%20Affairs%20facilities%2C%2014.6%25%20received%20SGLT2%20inhibitors.%20Patients%20receiving%20SGLT2%20inhibitors%20were%20younger%20men%20with%20higher%20hemoglobin%20A1c%20and%20estimated%20glomerular%20filtration%20rate%20and%20were%20more%20likely%20to%20have%20HF%20with%20reduced%20ejection%20fraction%20and%20ischemic%20heart%20disease.%20There%20was%20significant%20facility-level%20variation%20of%20SGLT2%20inhibitor%20use%2C%20with%20an%20adjusted%20median%20rate%20ratio%20of%201.55%20%2895%25%5Cu00a0CI%3A%201.46-1.64%29%2C%20indicating%20a%2055%25%20residual%20difference%20in%20SGLT2%20inhibitor%20use%20among%20similar%20patients%20with%20ASCVD%2C%20HF%2C%20and%20T2DM%20receiving%20care%20at%202%20random%20facilities.%5CnCONCLUSIONS%3A%20Utilization%20rates%20of%20SGLT2%20inhibitors%20are%20low%20in%20patients%20with%20ASCVD%2C%20HF%2C%20and%20T2DM%2C%20with%20high%20residual%20facility-level%20variation.%20These%20findings%20suggest%20opportunities%20to%20optimize%20SGLT2%20inhibitor%20use%20to%20prevent%20future%20adverse%20cardiovascular%20events.%22%2C%22date%22%3A%222023-05-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2023.03.024%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%227DBQSZ99%22%2C%22GL8QP2FN%22%2C%22FCV4W3RS%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T18%3A07%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22HLA3PRJL%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cuchel%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCuchel%2C%20M.%2C%20Lee%2C%20P.%20C.%2C%20Hudgins%2C%20L.%20C.%20et%20al.%20%282023%29.%20Contemporary%20homozygous%20familial%20hypercholesterolemia%20in%20the%20United%20States%3A%20Insights%20from%20the%20CASCADE%20FH%20Registry.%20%26lt%3Bi%26gt%3BJ%20Am%20Heart%20Assoc%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B12%26lt%3B%5C%2Fi%26gt%3B%2C%20e029175.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.029175%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.029175%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Contemporary%20homozygous%20familial%20hypercholesterolemia%20in%20the%20United%20States%3A%20Insights%20from%20the%20CASCADE%20FH%20Registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Cuchel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20C.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%20C.%22%2C%22lastName%22%3A%22Hudgins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Barton%22%2C%22lastName%22%3A%22Duell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zahid%22%2C%22lastName%22%3A%22Ahmad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seth%20J.%22%2C%22lastName%22%3A%22Baum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22MacRae%20F.%22%2C%22lastName%22%3A%22Linton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20D.%22%2C%22lastName%22%3A%22de%20Ferranti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20A.%22%2C%22lastName%22%3A%22Larry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%20C.%22%2C%22lastName%22%3A%22Hemphill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iris%22%2C%22lastName%22%3A%22Kindt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20S.%22%2C%22lastName%22%3A%22Gidding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seth%20S.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20M.%22%2C%22lastName%22%3A%22Moriarty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20P.%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20A.%22%2C%22lastName%22%3A%22Underberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20R.%22%2C%22lastName%22%3A%22Guyton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rolf%20L.%22%2C%22lastName%22%3A%22Andersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Whellan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irwin%22%2C%22lastName%22%3A%22Benuck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20P.%22%2C%22lastName%22%3A%22Kane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%22%2C%22lastName%22%3A%22Myers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Howard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Staszak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allison%22%2C%22lastName%22%3A%22Jamison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%20C.%22%2C%22lastName%22%3A%22Card%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mafalda%22%2C%22lastName%22%3A%22Bourbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joana%20R.%22%2C%22lastName%22%3A%22Chora%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20J.%22%2C%22lastName%22%3A%22Rader%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joshua%20W.%22%2C%22lastName%22%3A%22Knowles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katherine%22%2C%22lastName%22%3A%22Wilemon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%20P.%22%2C%22lastName%22%3A%22McGowan%22%7D%5D%2C%22abstractNote%22%3A%22Background%20Homozygous%20familial%20hypercholesterolemia%20%28HoFH%29%20is%20a%20rare%2C%20treatment-resistant%20disorder%20characterized%20by%20early-onset%20atherosclerotic%20and%20aortic%20valvular%20cardiovascular%20disease%20if%20left%20untreated.%20Contemporary%20information%20on%20HoFH%20in%20the%20United%20States%20is%20lacking%2C%20and%20the%20extent%20of%20underdiagnosis%20and%20undertreatment%20is%20uncertain.%20Methods%20and%20Results%20Data%20were%20analyzed%20from%2067%20children%20and%20adults%20with%20clinically%20diagnosed%20HoFH%20from%20the%20CASCADE%20%28Cascade%20Screening%20for%20Awareness%20and%20Detection%29%20FH%20Registry.%20Genetic%20diagnosis%20was%20confirmed%20in%2043%20patients.%20We%20used%20the%20clinical%20characteristics%20of%20genetically%20confirmed%20patients%20with%20HoFH%20to%20query%20the%20Family%20Heart%20Database%2C%20a%20US%20anonymized%20payer%20health%20database%2C%20to%20estimate%20the%20number%20of%20patients%20with%20similar%20lipid%20profiles%20in%20a%20%26quot%3Breal-world%26quot%3B%20setting.%20Untreated%20low-density%20lipoprotein%20cholesterol%20levels%20were%20lower%20in%20adults%20than%20children%20%28533%20versus%20776%5Cu2009mg%5C%2FdL%3B%20P%3D0.001%29.%20At%20enrollment%2C%20atherosclerotic%20cardiovascular%20disease%20and%20supravalvular%20and%20aortic%20valve%20stenosis%20were%20present%20in%2078.4%25%20and%2043.8%25%20and%2025.5%25%20and%2018.8%25%20of%20adults%20and%20children%2C%20respectively.%20At%20most%20recent%20follow-up%2C%20despite%20multiple%20lipid-lowering%20treatment%2C%20low-density%20lipoprotein%20cholesterol%20goals%20were%20achieved%20in%20only%20a%20minority%20of%20adults%20and%20children.%20Query%20of%20the%20Family%20Heart%20Database%20identified%20277%20individuals%20with%20profiles%20similar%20to%20patients%20with%20genetically%20confirmed%20HoFH.%20Advanced%20lipid-lowering%20treatments%20were%20prescribed%20for%2018%25%3B%2040%25%20were%20on%20no%20lipid-lowering%20treatment%3B%20atherosclerotic%20cardiovascular%20disease%20was%20reported%20in%2020%25%3B%20familial%20hypercholesterolemia%20diagnosis%20was%20uncommon.%20Conclusions%20Only%20patients%20with%20the%20most%20severe%20HoFH%20phenotypes%20are%20diagnosed%20early.%20HoFH%20remains%20challenging%20to%20treat.%20Results%20from%20the%20Family%20Heart%20Database%20indicate%20HoFH%20is%20systemically%20underdiagnosed%20and%20undertreated.%20Earlier%20screening%2C%20aggressive%20lipid-lowering%20treatments%2C%20and%20guideline%20implementation%20are%20required%20to%20reduce%20disease%20burden%20in%20HoFH.%22%2C%22date%22%3A%222023-05-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.122.029175%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T15%3A01%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22URB66KN3%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Virani%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVirani%2C%20S.%20S.%2C%20Ramsey%2C%20D.%20J.%2C%20Westerman%2C%20D.%20et%20al.%20%282023%29.%20Cluster%20randomized%20trial%20of%20a%20personalized%20clinical%20decision%20support%20intervention%20to%20improve%20statin%20prescribing%20in%20patients%20with%20atherosclerotic%20cardiovascular%20disease.%20%26lt%3Bi%26gt%3BCirculation%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B147%26lt%3B%5C%2Fi%26gt%3B%2C%201411%26%23x2013%3B1413.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCULATIONAHA.123.064226%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCULATIONAHA.123.064226%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cluster%20randomized%20trial%20of%20a%20personalized%20clinical%20decision%20support%20intervention%20to%20improve%20statin%20prescribing%20in%20patients%20with%20atherosclerotic%20cardiovascular%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20S.%22%2C%22lastName%22%3A%22Virani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Ramsey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dax%22%2C%22lastName%22%3A%22Westerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20K.%22%2C%22lastName%22%3A%22Kuebeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liang%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%20M.%22%2C%22lastName%22%3A%22Akeroyd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Glenn%20T.%22%2C%22lastName%22%3A%22Gobbel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20A.%22%2C%22lastName%22%3A%22Petersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Turchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20E.%22%2C%22lastName%22%3A%22Matheny%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-05-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.123.064226%22%2C%22ISSN%22%3A%221524-4539%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%22FCV4W3RS%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T15%3A01%3A00Z%22%7D%7D%5D%7D
Ijaz, S. H., Minhas, A. M. K., Jain, V. et al. (2023). Characteristics and outcomes in acute myocardial infarction hospitalizations among the older population (age ≥80 years) in the United States, 2004-2018. Arch Gerontol Geriatr 111, 104930. https://doi.org/10.1016/j.archger.2023.104930.
Ballantyne, C. M. and Jia, X. (2023). Omega-3 fatty acids and risk for atrial fibrillation: big fish or small fry? J Am Coll Cardiol 82, 350–352. https://doi.org/10.1016/j.jacc.2023.05.026.
Walker, K. A., Chen, J., Shi, L. et al. (2023). Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life. Sci Transl Med 15, eadf5681. https://doi.org/10.1126/scitranslmed.adf5681.
Jia, X., Buckley, L., Sun, C. et al. (2023). Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis risk in communities study. Eur J Prev Cardiol, zwad197. https://doi.org/10.1093/eurjpc/zwad197.
Kiernan, E., Surapaneni, A., Zhou, L. et al. (2023). Alterations in the circulating proteome associated with albuminuria. J Am Soc Nephrol 34, 1078–1089. https://doi.org/10.1681/ASN.0000000000000108.
Ballantyne, C. M., Ditmarsch, M., Kastelein, J. J. et al. (2023). Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol, S1933-2874(23)00186–1. https://doi.org/10.1016/j.jacl.2023.05.098.
Zhang, Y., Dron, J. S., Bellows, B. K. et al. (2023). Association of severe hypercholesterolemia and familial hypercholesterolemia genotype with risk of coronary heart disease. Circulation 147, 1556–1559. https://doi.org/10.1161/CIRCULATIONAHA.123.064168.
Hussain, A., Ramsey, D., Lee, M. et al. (2023). Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: Insights from the Department of Veterans Affairs. JACC Heart Fail, S2213-1779(23)00185–3. https://doi.org/10.1016/j.jchf.2023.03.024.
Cuchel, M., Lee, P. C., Hudgins, L. C. et al. (2023). Contemporary homozygous familial hypercholesterolemia in the United States: Insights from the CASCADE FH Registry. J Am Heart Assoc 12, e029175. https://doi.org/10.1161/JAHA.122.029175.
Virani, S. S., Ramsey, D. J., Westerman, D. et al. (2023). Cluster randomized trial of a personalized clinical decision support intervention to improve statin prescribing in patients with atherosclerotic cardiovascular disease. Circulation 147, 1411–1413. https://doi.org/10.1161/CIRCULATIONAHA.123.064226.